Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record.

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

Open access
Naumann, R, Beuthien-Baumann, B, Reiß, A, Schulze, J, Hänel, A, Bredow, J, Kühnel, G, Kropp, J, Hänel, M, Laniado, M, Kotzerke, J, Ehninger, G·2004·British Journal of Cancer

Abstract

This prospective study assessed the impact of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the staging and possible consequential changes of treatment regimen in patients with Hodgkin's lymphoma (HL). A total of 88 consecutive patients with histologically verified Hodgkin's lymphoma underwent a PET scan in addition to conventional staging procedures. Treatment was based on the conventional staging only, and the results of the FDG-PET did not affect the treatment strategy. The evaluation focused on the suggested change in clinical stage according to the Ann Arbor classification and on the suggested change in treatment strategy rather than on a lesion-by-lesion analysis. Using all the methods performed as the standard of reference, (18)F-FDG-PET staging was concordant with conventional staging in 70 out of 88 patients (80%). (18)F-fluorodeoxyglucose positron emission tomography suggested a change to a different clinical stage in 18 patients (20%). Management would have been changed in 16 patients (18%): intensification of treatment in nine patients (10%) and minimisation of treatment in seven patients (8%). In the 44 patients with early disease (stage IA-IIB), treatment would have been intensified in nine out of 44 patients (20%). (18)F-fluorodeoxyglucose positron emission tomography is a relevant noninvasive method that supplements conventional staging procedures and should therefore be used routinely to stage Hodgkin's lymphoma, particularly in patients with an early stage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6601561

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 171

Metadata

Authors
Naumann, R., Beuthien-Baumann, B., Reiß, A., Schulze, J., Hänel, A., Bredow, J., Kühnel, G., Kropp, J., Hänel, M., Laniado, M., Kotzerke, J., & Ehninger, G.
Venue
British Journal of Cancer
Published
2004-02
Volume
90
Issue
3
Pages
620-625
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1990524729
Cited by
171
References
0
FWCI
10.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6601561
The paper
Naumann, R., Beuthien-Baumann, B., Reiß, A., Schulze, J., Hänel, A., Bredow, J., Kühnel, G., Kropp, J., Hänel, M., Laniado, M., Kotzerke, J., & Ehninger, G. (2004). Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.